Company Performance - Sight Sciences, Inc. reported a quarterly loss of $0.28 per share, which was better than the Zacks Consensus Estimate of a loss of $0.29, and an improvement from a loss of $0.33 per share a year ago, indicating an earnings surprise of 3.45% [1] - The company posted revenues of $17.51 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 5.95%, although this represents a decline from year-ago revenues of $19.27 million [2] - Over the last four quarters, Sight Sciences has exceeded consensus EPS estimates three times and has topped consensus revenue estimates three times as well [2] Stock Performance - Sight Sciences shares have declined approximately 21.4% since the beginning of the year, contrasting with the S&P 500's decline of 4.3% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.30 on revenues of $18.38 million, and for the current fiscal year, it is -$1.15 on revenues of $72.02 million [7] Industry Outlook - The Medical - Instruments industry, to which Sight Sciences belongs, is currently ranked in the top 28% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Serve Robotics Inc. (SERV) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.37 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 23.81%. A quarter ago, it was expected that this company would post a loss of $0.19 per share when it actually produced a loss of $0.23, delivering a surprise of -21.05%.Over the last four quarters, the company has sur ...

Company Performance - Onto Innovation (ONTO) reported quarterly earnings of $1.51 per share, exceeding the Zacks Consensus Estimate of $1.47 per share, and up from $1.18 per share a year ago, representing an earnings surprise of 2.72% [1] - The company posted revenues of $266.61 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.62%, and an increase from $228.85 million year-over-year [2] - Onto Innovation has consistently surpassed consensus EPS and revenue estimates over the last four quarters [2] Stock Outlook - The stock has underperformed, losing about 24.9% since the beginning of the year, compared to the S&P 500's decline of 4.3% [3] - The current consensus EPS estimate for the upcoming quarter is $1.48 on revenues of $264.6 million, and for the current fiscal year, it is $6.09 on revenues of $1.07 billion [7] Industry Context - The Nanotechnology industry, to which Onto Innovation belongs, is currently ranked in the bottom 6% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of Onto Innovation's stock may be influenced by the overall outlook for the industry, as research shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Core Insights - Dropbox reported quarterly earnings of $0.70 per share, exceeding the Zacks Consensus Estimate of $0.62 per share, and up from $0.58 per share a year ago, representing an earnings surprise of 12.90% [1] - The company posted revenues of $624.7 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.91%, although down from $631.3 million year-over-year [2] - Dropbox has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Earnings Performance - The earnings surprise for the previous quarter was 17.74%, with actual earnings of $0.73 per share against an expectation of $0.62 [1] - The current consensus EPS estimate for the upcoming quarter is $0.64, with projected revenues of $618.61 million, and for the current fiscal year, the estimate is $2.54 on $2.47 billion in revenues [7] Market Position - Dropbox shares have declined approximately 2.1% since the beginning of the year, while the S&P 500 has seen a decline of 4.3% [3] - The Zacks Industry Rank places the Internet - Services sector in the bottom 40% of over 250 Zacks industries, indicating potential challenges for stock performance [8] Future Outlook - The sustainability of Dropbox's stock price movement will largely depend on management's commentary during the earnings call and future earnings expectations [3][4] - The estimate revisions trend for Dropbox is currently mixed, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6]

Group 1 - Cardiff Oncology reported a quarterly loss of $0.20 per share, slightly worse than the Zacks Consensus Estimate of a loss of $0.19, but an improvement from a loss of $0.22 per share a year ago, indicating a -5.26% earnings surprise [1] - The company posted revenues of $0.11 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 33.94%, and down from $0.21 million in the same quarter last year [2] - Cardiff Oncology shares have declined approximately 42.6% since the beginning of the year, contrasting with the S&P 500's decline of -4.3% [3] Group 2 - The earnings outlook for Cardiff Oncology is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The trend for estimate revisions for Cardiff Oncology is currently favorable, leading to a Zacks Rank 2 (Buy) for the stock, suggesting it is expected to outperform the market in the near future [6] - The current consensus EPS estimate for the upcoming quarter is -$0.19 on revenues of $0.17 million, and for the current fiscal year, it is -$0.78 on revenues of $0.65 million [7] Group 3 - The Medical - Biomedical and Genetics industry, to which Cardiff Oncology belongs, is currently ranked in the top 33% of over 250 Zacks industries, indicating a favorable outlook for stocks in this sector [8] - Another company in the same industry, Immatics, is expected to report a quarterly loss of $0.39 per share, reflecting a significant year-over-year decline of -875%, with revenues projected to be $14.9 million, down 54.7% from the previous year [9]

Company Performance - BioLife Solutions, Inc. reported quarterly earnings of $0.04 per share, exceeding the Zacks Consensus Estimate of a loss of $0.03 per share, and showing improvement from a loss of $0.19 per share a year ago, resulting in an earnings surprise of 233.33% [1] - The company achieved revenues of $23.94 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 5.28%, although this represents a decline from year-ago revenues of $31.73 million [2] - Over the last four quarters, BioLife Solutions has consistently surpassed consensus EPS estimates [2] Stock Performance - BioLife Solutions shares have declined approximately 17.8% since the beginning of the year, in contrast to the S&P 500's decline of 4.3% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.03 on revenues of $23.29 million, and for the current fiscal year, it is -$0.09 on revenues of $97.18 million [7] Industry Outlook - The Medical - Products industry, to which BioLife Solutions belongs, is currently ranked in the bottom 32% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of BioLife Solutions may be influenced by the overall outlook of the industry, as historical data shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Group 1 - Expedia reported quarterly earnings of $0.40 per share, missing the Zacks Consensus Estimate of $0.42 per share, but showing an increase from $0.21 per share a year ago, resulting in an earnings surprise of -4.76% [1] - The company posted revenues of $2.99 billion for the quarter ended March 2025, missing the Zacks Consensus Estimate by 1.27%, compared to $2.89 billion in the same quarter last year [2] - Over the last four quarters, Expedia has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Group 2 - The stock has underperformed, losing about 10.6% since the beginning of the year, while the S&P 500 declined by -4.3% [3] - The current consensus EPS estimate for the coming quarter is $4.05 on revenues of $3.74 billion, and for the current fiscal year, it is $14.31 on revenues of $14.33 billion [7] - The Zacks Industry Rank indicates that the Internet - Commerce sector is currently in the top 30% of over 250 Zacks industries, suggesting a favorable outlook for the industry [8]

Core Viewpoint - Collegium Pharmaceutical reported quarterly earnings of $1.49 per share, exceeding the Zacks Consensus Estimate of $1.43 per share, and showing a slight increase from $1.45 per share a year ago, indicating a 4.20% earnings surprise [1][2] Financial Performance - The company achieved revenues of $177.76 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 3.08%, and up from $144.92 million in the same quarter last year [2] - Over the last four quarters, Collegium Pharmaceutical has exceeded consensus EPS estimates three times and has topped consensus revenue estimates three times as well [2] Stock Performance - Collegium Pharmaceutical shares have declined approximately 5.6% since the beginning of the year, compared to a decline of 4.3% for the S&P 500 [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating it is expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $1.61, with projected revenues of $181.28 million, and for the current fiscal year, the EPS estimate is $6.88 on revenues of $741.38 million [7] - The outlook for the Medical - Drugs industry, where Collegium operates, is favorable, ranking in the top 26% of over 250 Zacks industries, suggesting potential for outperformance [8]

Core Insights - Nerdy Inc. reported a quarterly loss of $0.09 per share, better than the Zacks Consensus Estimate of a loss of $0.14, representing an earnings surprise of 35.71% [1] - The company generated revenues of $47.6 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 3.24%, but down from $53.73 million year-over-year [2] - The stock has increased approximately 2.5% since the beginning of the year, contrasting with a -4.3% decline in the S&P 500 [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.10 on revenues of $46.65 million, and for the current fiscal year, it is -$0.42 on revenues of $192.53 million [7] - The estimate revisions trend for Nerdy is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Schools industry, to which Nerdy belongs, is currently in the top 30% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Lincoln Educational Services Corporation, another company in the same industry, is expected to report a quarterly earnings decline of 33.3% with revenues projected at $113.84 million, up 10.1% year-over-year [9][10]

Financial Performance - Celldex Therapeutics reported a quarterly loss of $0.81 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.75, and compared to a loss of $0.56 per share a year ago, indicating a decline in performance [1] - The company posted revenues of $0.7 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 62.29%, while revenues a year ago were $0.16 million [2] - Over the last four quarters, Celldex has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Performance - Celldex shares have declined approximately 25.2% since the beginning of the year, contrasting with the S&P 500's decline of 4.3% [3] - The current Zacks Rank for Celldex is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.81 on revenues of $1.84 million, and for the current fiscal year, it is -$3.38 on revenues of $7.33 million [7] - The estimate revisions trend for Celldex is mixed, and future earnings expectations will depend on management's commentary during the earnings call [3][4] Industry Context - The Medical - Biomedical and Genetics industry, to which Celldex belongs, is currently in the top 33% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Celldex's stock performance [5]